Molbé Capital Competitors

Now part of PerkinElmer, Cisbio develops and markets products and technologies used for in vitro diagnostics and drug discovery. With the proprietary technology, HTRF®, the organization is a leader in homogeneous fluorescence detection methods, and offers first-class assays and services for drug discovery researchers. In addition, Cisbio Bioassays provides a broad range of immunoassays for in vitro diagnostics, mainly tailored for cancerous pathologies, as well as metabolic and auto-immune diseases. Based in Codolet, France, Cisbio owns facilities in Bedford, MA, U.S.A., in Chiba, Japan and Shanghai, China, and markets its offering globally.

We are a leading biotechnology company for the development and marketing of detection & elimination kits for microbial contamination control. Our core competence lies in the control of mycoplasmas, bacteria and viruses in cell cultures and biopharmaceuticals. In addition, we offer specialized PCR kits and reagents for the screening of drinking water and food for germs and undeclared meat as well as for the quality assurance of halal and vegan products. Products for the qualification of PCR cyclers or the removal of DNA contaminations in the PCR laboratory complete our product portfolio. It is our mission to be your highly competent experts in extremely specialized areas of contamination control. We strive to provide first class products, which can be used with confidence in scientific research, clinical research, and in process and quality control in the biopharmaceutical industry.

ActivX was a biopharmaceutical company that discovered and developed highly selective, best in class, small molecule drugs for major unmet medical needs. ActivX used its unique technology to identify target and off-target activities of drug candidates in the protein kinase and protease families with a focus on hematology, oncology, metabolic and inflammatory diseases. Our core technology allows identification and development of highly selective drugs, lowering development risk.